Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 5/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | HEXA | P06865 | 3/20 | 0.35 |
| ▸ | HEXB | P07686 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049581 | 0.86 | SCN2A (0.44) | SCN2ASCN9ASCN3ASCN10AKCNH2 | |
| SCHEMBL5070888 | 0.84 | HSP90AA1 (0.48) | SMN1; SMN2KDM4EHSD17B10NPC1ALOX15 | |
| SCHEMBL6049467 | 0.84 | HTR2B (0.51) | SCN10AKCNH2SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL6049502 | 0.82 | SCN2A (0.39) | SCN2ASCN9ASCN3ASCN10AKCNH2 | |
| SCHEMBL5070759 | 0.81 | SCN9A (0.50) | SCN2ASCN9ASCN3ASCN10ASCN5A | |
| Hydrochloric Acid SCHEMBL5070910 | 0.79 | SCN9A (0.49) | SCN2ASCN9ASCN3ASCN10ASCN5A | |
| SCHEMBL7387066 | 0.78 | SCN2A (0.49) | SCN2ASCN9ASCN3ASCN10AKCNH2 | |
| SCHEMBL7272544 | 0.78 | ALDH1A1 (0.41) | KCNH2SMN1; SMN2KDM4EHSD17B10HTR2B | |
| SCHEMBL5070133 | 0.76 | SCN2A (0.46) | SCN2ASCN9ASCN3ASCN10AKCNH2 | |
| SCHEMBL8842601 | 0.76 | PIK3CA (0.46) | SCN2AKDM4EHSD17B10KCNK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1681058-A2 | Pharmacologically active cns compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2006-07-19 | — | — | EP | claimed |
| US-20040229873-A1 | Treatment of neurodegenerative conditions | BTG INTERNATIONAL LIMITED (GB) | 2004-11-18 | — | — | US | claimed |
| US-5587380-A | ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. (US) | 1996-12-24 | — | — | US | claimed |
| EP-0727214-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | claimed |
| EP-0727213-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | claimed |
| EP-0727212-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | claimed |
| EP-0715851-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-12 | — | — | EP | claimed |
| EP-0713703-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-29 | — | — | EP | claimed |
| CN-1052306-A | Compounds having pharmacological activity on the central nervous system | WELLCOME FOUND (GB) | 1991-06-19 | — | — | CN | claimed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | claimed |
| US-20140079757-A1 | ORAL DRUG DELIVERY FORMULATIONS | BROWN RUDNICK LLP | 2014-03-20 | — | — | US | disclosed |
| WO-2012028963-A2 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF | MS THERAPEUTICS LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
| US-20120058097-A1 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF | MS THERAPEUTICS LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-1325916-B1 | Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system | WELLCOME FOUND (GB) | 2008-01-23 | — | — | EP | disclosed |
| EP-1681058-A2 | Pharmacologically active cns compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2006-07-19 | — | — | EP | disclosed |
| EP-0715851-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-12 | — | — | EP | disclosed |
| EP-0713703-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-29 | — | — | EP | disclosed |
| CN-1117046-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-02-21 | — | — | CN | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058097-A1 | COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF | CACNA1B, KCNMB1, KCNB2 | SCN2A 25/4885SCN9A 38/4885SCN3A 31/4885 |
| US-20040229873-A1 | Treatment of neurodegenerative conditions | CHRM2, CHRNA3, CHRNA2 | SCN2A 63/4885SCN9A 230/4885SCN3A 33/4885 |
| US-20140079757-A1 | ORAL DRUG DELIVERY FORMULATIONS | PGF, MMP1, MMP26 | SCN2A 4830/4885SCN9A 4498/4885SCN3A 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.